证券代码：688426 证券简称：康为世纪 公告编号：2025-043 江苏康为世纪生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025 年 11 月 10 日（星期一）下午 16:00-17:00 1 / 3 ●会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于 2025 年 11 月 3 日（星期一）至 2025 年 11 月 7 日（星期五）中午 12:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IRM@cwbio.cn 进行提问。公司将在本次业绩说明会上对投资者普遍关注的、有代表性的问题逐条进行 回答。 江苏康为世纪生物科技股份有限公司(下称"公司")已于 2025 年 10 月 31 日在上海证 券交易所网站（www.sse.com.cn）披露了《2025 年第三季度报告》，为了 ...

Financial Performance - Revenue for Q3 2025 reached ¥52,455,562.72, an increase of 68.47% compared to the same period last year[3] - Total profit for Q3 2025 was -¥21,249,963.37, representing a decrease of 54.96% year-on-year[3] - Net profit attributable to shareholders for Q3 2025 was -¥20,251,462.35, a decline of 55.58% compared to the previous year[3] - Operating cash flow for Q3 2025 was -¥22,168,904.60, a decrease of 34.03% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥139,574,234.46, a significant increase from ¥98,283,588.99 in the same period of 2024, representing a growth of approximately 42%[18] - The operating profit for the first three quarters of 2025 was reported at -¥79,256,667.56, an improvement compared to -¥104,752,492.00 in 2024[19] - Net profit for the first three quarters of 2025 was -¥78,096,679.32, compared to -¥95,907,697.78 in the same period of 2024, indicating a reduction in losses[19] - The total comprehensive income attributable to the parent company was -76,162,854.28 CNY, compared to -95,645,454.09 CNY in the previous period, showing an improvement[20] - The company reported a basic and diluted earnings per share of -0.69 CNY, an improvement from -0.86 CNY in the prior period[20] Research and Development - R&D expenses totaled ¥18,092,442.60 in Q3 2025, down 30.50% from the previous year[4] - R&D expenses accounted for 34.49% of revenue in Q3 2025, a decrease of 49.11 percentage points year-on-year[4] - Research and development expenses for the first three quarters of 2025 amounted to ¥58,902,293.52, down from ¥72,049,404.79 in 2024, showing a decrease of approximately 18%[18] - The company optimized R&D resource allocation, focusing on market-oriented projects to enhance efficiency[8] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥1,550,833,825.96, a decrease of 4.16% from the end of the previous year[4] - Total liabilities increased to ¥141,692,635.09 from ¥131,788,713.04, marking an increase of about 7%[14] - The total equity attributable to shareholders decreased to ¥1,390,519,558.42 from ¥1,465,785,417.74, reflecting a decline of approximately 5.1%[14] - Cash and cash equivalents included in current assets totaled ¥1,087,753,273.02, compared to ¥833,404,226.85 in the previous period, indicating a growth of about 30.5%[15] - The company reported a decrease in short-term borrowings to ¥10,007,777.78 from ¥6,005,600.00, reflecting a strategic reduction in debt[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,905[10] - Beijing Kangwei Century Biotechnology Co., Ltd. holds 50,400,000 shares, accounting for 44.80% of total shares[10] - Taizhou Kangwei Co-Creation Enterprise Management Consulting Partnership holds 21,600,000 shares, representing 19.20% of total shares[10] - The top ten shareholders do not include any shares lent through margin trading[12] - The company has no significant changes in shareholder structure compared to the previous period[12] Cash Flow - The company's cash and cash equivalents as of September 30, 2025, amount to ¥184,205,974.30, down from ¥255,466,049.27 as of December 31, 2024[12] - The net cash flow from operating activities was -71,824,555.68 CNY, an improvement from -92,827,326.52 CNY year-over-year[21] - Cash received from the sale of goods and services increased to 126,143,516.94 CNY, up from 90,526,995.55 CNY in the same period last year, representing a growth of approximately 39.2%[21] - The company incurred operating cash outflows totaling 229,309,685.83 CNY, compared to 189,799,092.17 CNY in the previous year[21] - The company received cash inflows from investment activities totaling 1,219,429,294.81 CNY, compared to 707,660,113.86 CNY in the previous year[21] - The company’s cash outflows from financing activities were 14,202,559.75 CNY, compared to 54,328,194.97 CNY in the previous year, indicating a reduction in financing costs[21] Operational Highlights - The increase in revenue was primarily driven by significant growth in nanopore sequencing services[8] - There are no other important reminders regarding the company's operational situation during the reporting period[12] - The company did not execute any mergers or acquisitions during the reporting period[20]

证券代码：688426 证券简称：康为世纪 公告编号：2025-042 江苏康为世纪生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 29 日 （二） 股东会召开的地点：江苏省泰州市医药高新区泽兰路 18 号江苏康为世纪 生物科技股份有限公司 2 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 35 | | --- | --- | | 普通股股东人数 | 35 | | 2、出席会议的股东所持有的表决权数量 | 78,019,730 | | 普通股股东所持有表决权数量 | 78,019,730 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 70.9710 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 7 ...

致:江苏康为世纪生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受江苏康为世纪生物科技股份有限 公司(以下简称"公司")的委托,指派本所茹秋乐律师、周奇律师(以下简称"本所 律师")根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会 规则》等法律、法规以及规范性文件(以下统称"法律法规")及《江苏康为世纪生物 科技股份有限公司章程》(以下简称"公司章程")的规定就公司 2025 年第二次临时 股东会(以下简称"本次股东会")相关事宜出具法律意见。 上海市通力律师事务所关于江苏康为世纪生物科技股份有限公司 2025 年第二次临时股东会的法律意见书 香港 HONG KONG 伦敦 LONDON 本所及本所律师依据法律法规及本法律意见出具目以前已经发生或者存在的事实, 严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进行了充分的核查验证,保证 本法律意见所认定的事实真实、准确、完整,所发表的结论性意见合法、准确,不存在 虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本所律师已经对公司提供的与本次股东会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中 ...

Core Insights - As of October 24, a total of 98 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Yibin Paper, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Juxing Technology, Laofengxiang, Kangwei Century, Tebao Biological, Daimei Co., Zhejiang Wenhu Internet, Huakang Clean, and Fuyuan Medical [1]

Core Insights - A total of 73 stocks in the Shanghai and Shenzhen markets have received net buying from major funds for five consecutive days or more as of October 23 [1] - The stock with the longest consecutive net buying days is Yongmaotai, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Yibin Paper, Hanghua Co., Baofeng Energy, Laofengxiang, Juxing Technology, Naxinwei, Daimei Co., and Kangwei Century [1]

Market Overview - The net outflow of main funds in the Shanghai and Shenzhen markets reached 33.733 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 1.968 billion yuan [1] - A total of 229 stocks saw net inflows, while 360 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 227 stocks rose while 351 stocks fell [1] - The top three stocks with the highest net inflow were: - Semiconductor Manufacturing International Corporation (SMIC) with a net inflow of 536 million yuan - Tuojing Technology with a net inflow of 236 million yuan - Guodun Quantum with a net inflow of 152 million yuan [1][2] Continuous Fund Flow Analysis - There are 56 stocks that have seen continuous net inflows for more than three trading days, with Kangwei Century leading at 15 consecutive days of inflow [2] - Conversely, 135 stocks have experienced continuous net outflows, with Hangke Technology leading at 16 consecutive days of outflow [2] Top Fund Inflows - The top stocks by net inflow are as follows: - SMIC: 536.39 million yuan, with a flow rate of 6.67% and a price increase of 1.17% [2] - Tuojing Technology: 236.32 million yuan, with a flow rate of 9.46% and a price increase of 3.89% [2] - Guodun Quantum: 152.30 million yuan, with a flow rate of 6.51% and a price increase of 9.06% [2] Notable Outflows - The stocks with the highest net outflows include: - Haiguang Information with a net outflow of 330 million yuan and a price drop of 2.33% [1] - Huahong Semiconductor with a net outflow of 230 million yuan [1] - Dongxin Technology with a net outflow of 162 million yuan [1]

Core Insights - The medical device sector experienced a slight increase of 0.01% on October 23, with Chen Guang Medical leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22% to 13025.45 [1] Medical Device Sector Performance - Chen Guang Medical (code: 920300) saw a significant rise of 16.01%, closing at 19.20 with a trading volume of 126,000 shares and a transaction value of 230 million [1] - Other notable gainers included Shuoshi Biology (code: 6628899) with a 7.07% increase, closing at 75.38, and Kangwei Century (code: 688426) which rose by 5.17% to 28.70 [1] - Conversely, the sector also had some decliners, with Toukeng Life (code: 300642) dropping by 6.19% to 24.26, and Rejing Biology (code: 688068) decreasing by 4.07% to 165.15 [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 542 million from institutional investors, while retail investors saw a net inflow of 373 million [2] - Notable net inflows from retail investors were observed in several companies, including Sainuo Medical (code: 688108) with a net inflow of 1.33 billion [3] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active in the market [2][3]

Group 1 - The core point of the news is that Jiangsu Kangwei Century Biotechnology Co., Ltd. has seen a stock price increase of 5.5%, reaching 28.79 yuan per share, with a total market capitalization of 3.239 billion yuan [1] - The company specializes in the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales and 10.86% from services [1] - The company was established on September 3, 2010, and was listed on October 25, 2022 [1] Group 2 - According to data, the fund "Shenwan Lixin Medical Pioneer Stock A" holds a significant position in Kangwei Century, having reduced its holdings by 12,000 shares in the second quarter, now holding 445,600 shares, which constitutes 7.43% of the fund's net value [2] - The fund has experienced a loss of 7% this year, ranking 4215 out of 4218 in its category, and a loss of 10.41% over the past year, ranking 3867 out of 3875 [2] - The fund manager, Yao Hongfu, has been in charge for 3 years and 98 days, with the best and worst fund returns during his tenure being -31.23% and -32.27%, respectively [3]

Market Overview - The net outflow of main funds in the Shanghai and Shenzhen markets reached 44.231 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 290 million yuan [1] - A total of 251 stocks saw net inflows, while 338 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 156 stocks rose, with one stock, Silin Jie, hitting the daily limit, while 423 stocks declined [1] - The top three stocks with the highest net inflow of main funds were Haiguang Information (net inflow of 642 million yuan), Dingtong Technology (228.6018 million yuan), and Hanwujing-U (198.2726 million yuan) [2] Continuous Fund Flow Analysis - There are 58 stocks with continuous net inflows for more than three trading days, with Kangwei Century leading at 14 consecutive days of inflow [2] - Conversely, 143 stocks experienced continuous net outflows, with Hangke Technology leading at 15 consecutive days of outflow [2] Key Stocks with Significant Fund Flows - The top stocks by net inflow include: - Haiguang Information: 64.192 million yuan, 7.43% inflow rate, 2.06% increase [2] - Dingtong Technology: 22.860 million yuan, 16.22% inflow rate, 1.24% increase [2] - Hanwujing-U: 19.827 million yuan, 1.00% inflow rate, 4.42% increase [2] - The stocks with the highest net outflows include: - Huahong Company: 31.8 million yuan outflow, 1.59% decrease [1] - Yuanjie Technology: 30.3 million yuan outflow [1] - Kingsoft Office: 15.9 million yuan outflow [1]